Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Merck
Mallinckrodt
McKesson
Express Scripts
Boehringer Ingelheim

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

MAKENA (AUTOINJECTOR) Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Makena (autoinjector), and when can generic versions of Makena (autoinjector) launch?

Makena (autoinjector) is a drug marketed by Amag Pharma Usa and is included in one NDA. There are eight patents protecting this drug.

This drug has forty-nine patent family members in fourteen countries.

The generic ingredient in MAKENA (AUTOINJECTOR) is hydroxyprogesterone caproate. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the hydroxyprogesterone caproate profile page.

Drug patent expirations by year for MAKENA (AUTOINJECTOR)
Recent Litigation for MAKENA (AUTOINJECTOR)

Identify potential future generic entrants

District Court Litigation
Case NameDate
Antares Pharma Inc. v. Medac Pharma Inc.2014-07-21

See all MAKENA (AUTOINJECTOR) litigation

US Patents and Regulatory Information for MAKENA (AUTOINJECTOR)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amag Pharma Usa MAKENA (AUTOINJECTOR) hydroxyprogesterone caproate SOLUTION;SUBCUTANEOUS 021945-004 Feb 14, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Amag Pharma Usa MAKENA (AUTOINJECTOR) hydroxyprogesterone caproate SOLUTION;SUBCUTANEOUS 021945-004 Feb 14, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Amag Pharma Usa MAKENA (AUTOINJECTOR) hydroxyprogesterone caproate SOLUTION;SUBCUTANEOUS 021945-004 Feb 14, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Amag Pharma Usa MAKENA (AUTOINJECTOR) hydroxyprogesterone caproate SOLUTION;SUBCUTANEOUS 021945-004 Feb 14, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
AstraZeneca
Harvard Business School
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.